In the News
The Burrill Report interviews Greg Scott on WuXi/CRL breakup and China's hot IPOs Greg Scott joined Foley's Eye on China webinar on life science innovation >>Foley webinar...
|
WuXi PharmaTech’s 2008 Meets Expectations, Though AppTec Disappoints
publication date: Mar 26, 2009
WuXi PharmaTech (药明康德) met, but didn’t beat, its 2008 financial guidance goals and admitted that its $151 million AppTec acquisition has not performed up to expectations. WuXi shut down AppTec’s US-based biologics manufacturing operations in December of 2008, saying it did not see any resurgence in that sector. However, AppTec’s biopharma and medical device testing business is continuing. WuXi Chairman and CEO Ge Li blamed AppTec’s disappointing performance on the larger economic crisis, which curtailed demand for contract biologics manufacturing. More details... Stock Symbol: (NYSE: WX)
|
Partner Events
BioPharm America™ 2010Boston, MA, USA September 15–17, 2010 CALAsia 2010San Diego, USA October 4-5, 2010 CHINA PRETRIALS 2010: Global Preclinical Development Summit Beijing, China October 17-19, 2010 CHINA TRIALS 2010 Beijing, China November 7-9, 2010 12th Shanghai International Forum on Biotechnology & Pharmaceutical Industry (BIO-FORUM) Beijing, China November 9-11, 2010
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners
![]()
|